Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2016

View Archived Issues

Phase I studies show target engagement, acute GI symptoms with NexVax2 in HLA DQ2.5 celiac disease

BioRap and Pfizer enter agreement to develop new immunomodulators

NanoViricides enters partnership to further FluCide-I program

Grunenthal licenses European and Latin American rights to Zurampic from AstraZeneca

Incyte establishes collaboration to conduct several Moffitt blood cancer research programs

Dermira reports topline results from pivotal trials of DRM-04 for primary axillary hyperhidrosis

RegeneRx Biopharmaceuticals and Lee's Pharmaceutical accelerate development of RGN-259

Novartis plans phase III trials of subcutaneous ofatumumab in relapsing MS

BGN gene defects may cause an X-linked syndromic form of severe TAAD

FDA grants rare pediatric disease designation to Therabron's rhCC10

Corcept Therapeutics updates status of cortisol modulation programs in oncology

University College Cardiff Consultants patents AR modulators

Merck & Co. discloses sGC activators

Takeda Pharmaceutical describes GPR139 agonists

Eli Lilly and Company develops PKC inhibitors

Esteve presents dual sigma1 and mu-opioid receptor ligands

Pharosgen patent reveals anticancer agents

Shire completes combination with Baxalta

Deutetrabenazine shows promise for the treatment of for TD-related abnormal involuntary movements

Vectura's phase I trial of VR-942 meets primary objective

CSF exposure and proof of mechanism seen for cognitive impairment treatment BI-425809

Bellicum Pharmaceuticals enters research agreement with LUMC

Treos Bio developing precision cancer vaccines paired to companion diagnostics

Kiadis plans European MAA for ATIR-101

Astellas and Medivation plan phase III trial of enzalutamide for triple-negative breast cancer

Nektar Therapeutics reaches agreement with Daiichi Sankyo Europe for Onzeald

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...